Equity Profile

RGEN

REPLIGEN CORP

Health CareLife Sciences Tools & Services$6.9B

May5Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Repligen Corporation Beats on EPS, Stock Up 6.26%

Metric	Actual	Expected	Surprise
EPS	$0.48	$0.38	+25.00%
Revenue	—	$192M	—

management commentary, guidance changes, and full analysis available with Pro.

Repligen Corporation Beats on EPS, Stock Up 6.26%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.48	$0.38	+25.00%
Revenue	—	$192M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Repligen Corporation reported better-than-expected earnings per share, which likely contributed to the positive stock reaction of 6.26%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may view the EPS beat as a sign of operational strength, but the lack of revenue data could raise questions about future growth prospects.

Company Snapshot

Repligen Corporation (RGEN) operates in the health care sector, specifically in life sciences tools and services. The company focuses on providing products and services that support the development and manufacturing of biologic drugs, which are increasingly important in modern medicine.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

0.38

Revenue

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

192M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In the last quarter, Repligen reported an EPS of $0.49, exceeding expectations by 11.36%. However, the stock saw a slight decline the following day.

Management Promises & Guidance

Continue to innovate in bioprocessing technologies.
Expand market presence in biologics manufacturing.
Maintain strong customer relationships and support.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Repligen's upcoming earnings, expecting solid EPS and revenue figures. However, the market is also wary of potential misses given recent volatility.

Bull Case

If Repligen beats expectations, it could signal strong demand for its products and a robust growth trajectory, potentially boosting investor confidence.

Bear Case

Conversely, a miss on earnings or revenue could raise concerns about market demand and operational efficiency, leading to a negative reaction.

Key Metrics to Watch

EPS

0.38

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

192M

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Repligen achieve an EPS of at least $0.38?

This figure is crucial for assessing the company's profitability and could influence investor sentiment significantly.

How does the revenue of $192M compare to previous quarters?

Revenue growth is a key indicator of business health and market demand, and any shortfall could raise concerns.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Repligen's ability to leverage its product portfolio effectively, especially given recent innovations.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders expect volatility that may not align with consensus expectations.

Key Risk

If the company reports revenue significantly below $192M, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to sustain growth amidst increasing competition in the life sciences sector.

Bull Confirmed If

An EPS of $0.40 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.37 would indicate potential issues in profitability and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±10.84%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±13.3% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.8%

Calls (73K)P/C Ratio: 1.33Puts (98K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$536,480.00

3,832 sh

1 insider

Net

$536,480.00

Net selling

Most Active Insiders· 1 open-market trade

Chief Executive OfficerLoeillot Olivier
$536,480.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests the stock could rise by an average of +3.57%, confirming a strong growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted response as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of +0.58% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in bioprocessing.
2Insights into customer demand trends and market expansion efforts.
3Management's commentary on operational efficiency and cost management.
4Details on any new partnerships or collaborations in the life sciences sector.
5Guidance on future revenue expectations and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

0.38

Revenue

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

192M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In the last quarter, Repligen reported an EPS of $0.49, exceeding expectations by 11.36%. However, the stock saw a slight decline the following day.

Management Promises & Guidance

Continue to innovate in bioprocessing technologies.
Expand market presence in biologics manufacturing.
Maintain strong customer relationships and support.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Repligen's upcoming earnings, expecting solid EPS and revenue figures. However, the market is also wary of potential misses given recent volatility.

Bull Case

If Repligen beats expectations, it could signal strong demand for its products and a robust growth trajectory, potentially boosting investor confidence.

Bear Case

Conversely, a miss on earnings or revenue could raise concerns about market demand and operational efficiency, leading to a negative reaction.

Key Metrics to Watch

EPS

0.38

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

192M

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Repligen achieve an EPS of at least $0.38?

This figure is crucial for assessing the company's profitability and could influence investor sentiment significantly.

How does the revenue of $192M compare to previous quarters?

Revenue growth is a key indicator of business health and market demand, and any shortfall could raise concerns.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Repligen's ability to leverage its product portfolio effectively, especially given recent innovations.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders expect volatility that may not align with consensus expectations.

Key Risk

If the company reports revenue significantly below $192M, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to sustain growth amidst increasing competition in the life sciences sector.

Bull Confirmed If

An EPS of $0.40 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.37 would indicate potential issues in profitability and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±10.84%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±13.3% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.8%

Calls (73K)P/C Ratio: 1.33Puts (98K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$536,480.00

3,832 sh

1 insider

Net

$536,480.00

Net selling

Most Active Insiders· 1 open-market trade

Chief Executive OfficerLoeillot Olivier
$536,480.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests the stock could rise by an average of +3.57%, confirming a strong growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted response as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of +0.58% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in bioprocessing.
2Insights into customer demand trends and market expansion efforts.
3Management's commentary on operational efficiency and cost management.
4Details on any new partnerships or collaborations in the life sciences sector.
5Guidance on future revenue expectations and market conditions.